Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of actionCombines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour typesTransaction valued at up to $1.5 billion including $1.1 billion cash upfront LONDON, July 06, 2026 (GLOBE NEWSWIRE) -- Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of payloads